EW · 8-K · 20261104PR000053
Guidance / Outlook
Edwards Lifesciences Corp · 2026-11-04 · Importance 79 · Surprise 68 · No source text
Edwards raised its full-year 2026 sales growth guidance to approximately 11.5%, from 10% to 11%, and TAVR growth guidance to 9.0%–9.5%, from 8%–9%. TMTT sales guidance increased to $780–$790 million from $760–$780 million, while adjusted EPS guidance is now $2.97–$3.05. For Q4 2026, the company projects sales of $1.67–$1.75 billion and adjusted EPS of $0.61–$0.69. It expects Q4 and subsequent growth to rely mainly on increased procedure volumes and less on share gains, and continues to reaffirm mid-single-digit Surgical growth guidance.
Key facts
- Edwards Lifesciences increased its 2026 total company sales growth guidance to approximately 11.5% from 10% to 11%. source
- Edwards Lifesciences increased its 2026 TAVR sales growth guidance to 9.0% to 9.5% from 8% to 9%. source
- Edwards Lifesciences increased its 2026 TMTT sales guidance to $780 million to $790 million from $760 million to $780 million. source
- Edwards Lifesciences increased its full-year 2026 sales growth guidance to approximately 11.5% from 10% to 11%. source
- Edwards Lifesciences increased its 2026 TAVR product group sales growth guidance to 9% to 9.5% from 8% to 9%. source
- Edwards Lifesciences increased its 2026 TMTT product group sales guidance to $780 million to $790 million from $760 million to $780 million. source
- Edwards Lifesciences projected Q4 2026 total sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69. source
- Edwards Lifesciences increased its 2026 adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05, representing 18% growth at the midpoint versus the prior year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| margin | positive | committed | +1.3% | Edwards Lifesciences expected full-year 2026 operating profit margin to be at the high end of its original 28% to 29% guidance range,… |
| revenue | positive | committed | — | Edwards Lifesciences increased its 2026 total company sales growth guidance to approximately 11.5% from 10% to 11%. |
| revenue | unclear | committed | — | Edwards Lifesciences projected Q4 2026 total sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69. |
| net_income | unclear | committed | — | Edwards Lifesciences projected Q4 2026 total sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69. |
| net_income | positive | committed | — | Edwards Lifesciences increased its 2026 adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05, representing 18% growth at the… |